News: Simtuzumab

We provide the latest news and info on Simtuzumab


Bidness ETC

Gilead's simtuzumab fails pancreatic cancer trial
PharmaTimes
The company has announced results from a Phase II study evaluating simtuzumab, an inhibitor of the lysyl oxidase-like-2 enzyme, in combination with current standard of care gemcitabine (Eli Lilly's Gemzar). The data show that the addition of simtuzumab ...
Gilead Down on Weak Simtuzumab Data and Sovaldi NewsZacks.com
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...MarketWatch
Gilead's simtuzumab fails Phase 2 trial (GILD)Seeking Alpha (registration)
StockWise Daily -Drug Discovery & Development
all 45 news articles »

Published on Monday 20th of April 2015 03:24:20 AM Read more...


Liver Cirrhosis and Fibrosis Therapeutics Pipeline Review H1 2015 Research ...
PR Newswire (press release)
... emricasan, F-351, GR-MD-01, GR-MD-02, GXHPC-1, Livercellgram, Monoclonal Antibodies to Antagonize Transforming Growth Factor Beta 1 for HCV associated Liver Cirrhosis, PTL-303, Px-104, rifaximin, simtuzumab, Stem Cell Therapy for Liver Cirrhosis ...

and more »

Published on Monday 20th of April 2015 03:24:20 AM Read more...


Regulus Soars As AstraZeneca Grabs NASH Drug Rights RGLS AZN GILD
Investor's Business Daily
Gilead Sciences (NASDAQ:GILD) has a NASH drug — simtuzumab — in phase-two testing. Gilead recently bought some NASH-related technology from Phenex Pharmaceuticals. In February, Merck (NYSE:MRK) made an investment in privately held NGM ...

and more »

Published on Monday 20th of April 2015 03:24:20 AM Read more...


Drug Discovery & Development

What Does Orphan Drug Approval For Gilead Sciences, Inc. (GILD)'s ...
InvestCorrectly
Gilead Sciences, Inc. (NASDAQ:GILD)'s monoclonal antibody Simtuzumab recently obtained orphan drug status as a treatment for a rare liver-related disorder – primary sclerosing cholangitis. The designation may provide Gilead increased patent protection ...
Gilead Sciences: A 'Logical' Deal That 'Fits Well'Barron's (blog)
Gilead Sciences Inc To Acquire Phenex's Liver-Disease ProgramBidness ETC
Gilead Sciences Just Received Orphan Drug Status For Liver TreatmentBenzinga

all 107 news articles »

Published on Monday 20th of April 2015 03:24:20 AM Read more...


Motley Fool

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
Motley Fool
Hepatitis C drugs now compose roughly half of Gilead's total revenue, and this trend is expected to continue going forward, especially after the company's monoclonal antibody, simtuzumab, failed to show any clinical benefit across a host of cancers.

and more »

Published on Monday 20th of April 2015 03:24:20 AM Read more...


For advanced pancreatic cancer, simtuzumab not significantly more effective ...
Oncology Nurse Advisor
Gilead Sciences, Inc. has announced results from their phase 2 trial studying simtuzumab plus gemcitabine for the treatment of patients with previously untreated advanced pancreatic cancer. Researchers found that patients who received gemcitabine in ...

Published on Monday 20th of April 2015 03:24:20 AM Read more...


CNBC

GenFit NASH Data Drives Up Rival Intercept ICPT CNAT GILD
Investor's Business Daily
Gilead Sciences (NASDAQ:GILD) also has a NASH drug called simtuzumab in phase two testing, and it recently acquired some preclinical technologies from Phenex Pharmaceuticals. Gilead stock was up nearly 2% in afternoon trading Thursday, but it didn't ...
Biotech Beat: 3/26/15 - Intercept Pharmaceuticals (ICPT)Seeking Alpha (registration)
Nomura Remains Buyers of Intercept Pharmaceuticals (ICPT) Following ...StreetInsider.com

all 34 news articles »

Published on Monday 20th of April 2015 03:24:20 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts